ClinicalTrials.gg
CompletedNCT00124735Updated Aug 24, 2016Results posted

A Study to Determine the Dose Requirements of Rocuronium Bromide (Zemuron®) in Pediatric and Adolescent Subjects (21048)(COMPLETED)(P05797)

A Phase 3 interventional study of Rocuronium bolus maintenance and rocuronium continuous infusion maintenance in Anesthesia, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2016-08-24.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
Up to 17 Years
Sex
All
01

Study summary

The primary purpose of this study is to determine the dose requirements of rocuronium bromide when administered as a bolus dose (a single, large dose) for intubation (insertion of a tube through the nose or mouth into the trachea to provide artificial ventilation) and when administered by either continuous infusion or bolus doses for maintenance of muscle relaxation in term neonates (birth to \<28 days old), infants (28 days to \<=3 months) and toddlers (>3 months to \<=2 years), children (2 years to less than or equal to 11 years of age), and adolescents (>11 years to less than or equal to 17 years of age).

02

Conditions studied

  • Anesthesia
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects from birth up to 17 years of age who are scheduled for surgery with an anticipated duration of anesthesia of about 2 hours or more requiring a maintenance muscle relaxation dose(s).

Exclusion criteria

Exclusion Criteria:

  • Subjects whose parent(s) or legal guardian(s) are not willing to give written consent and where applicable, subjects who have not given appropriate assent to participate in the trials will not be allowed to enter.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
149 participants (actual)

Study arms

  • Experimental
    Rocuronium bolus maintenance

    Rocuronium bolus maintenance

    Drug: Rocuronium bolus maintenance

  • Experimental
    Rocuronium continuous infusion maintenance

    Rocuronium continuous infusion maintenance

    Drug: rocuronium continuous infusion maintenance

Interventions

  • Subjects received a bolus dose of rocuronium for intubation followed by bolus doses for maintenance of muscle relaxation

    Also known as: Zemuron, ORG 9426

  • Subjects received a bolus dose of rocuronium for intubation followed by continuous infusion of rocuronium for maintenance of muscle relaxation

    Also known as: Zemuron, ORG 9426

06

What researchers measure

Primary outcomes

  1. Total Dose of Zemuron (Rocuronium) Administered

    Total dose from administration of intubating dose to reappearance of T3 (the third twitch of a Train of Four \[TOF\] stimulation) after the last maintenance bolus dose or discontinuation of Zemuron (rocuronium) infusion (Per protocol \[PP\] data set)

    Time frame: during surgery

Secondary outcomes

  1. Duration of Recovery of T4/T1 Ratio (TOF Fourth Twitch to First Twitch) 70%

    The time it takes for the the T4 to T1 ratio to reach 70%. The T4/T1 ratio is indicative of recovery. At complete recovery, the T4/T1 ratio is 1.0 (100%).

    Time frame: after surgery, from the reappearance of T3 after Zemuron(R) (rocuronium) infusion/last bolus dose of Zemuron(R) (rocuronium)

  2. Duration of Recovery of T4/T1 (TOF Fourth Twitch to First Twitch) Ratio 80%

    The time it takes for the the T4 to T1 ratio to reach 80%. The T4/T1 ratio is indicative of recovery. At complete recovery, the T4/T1 ratio is 1.0 (100%).

    Time frame: after surgery, from the reappearance of T3 after Zemuron(R) (rocuronium) infusion/last bolus dose of Zemuron(R) (rocuronium)

  3. Duration of Recovery of T4/T1 (TOF Fourth Twitch to First Twitch) Ratio 90%

    The time it takes for the the T4 to T1 ratio to reach 90%. The T4/T1 ratio is indicative of recovery. At complete recovery, the T4/T1 ratio is 1.0 (100%).

    Time frame: after surgery, from the reappearance of T3 after Zemuron(R) (rocuronium) infusion/last bolus dose of Zemuron(R) (rocuronium)

07

Results

Posted Apr 15, 2009

Participant flow

Participant flow — Overall Study
MilestoneRocuronium Bolus Maintenance - Neonate (BN)Rocuronium Bolus Maintenance - Infants (BI)Rocuronium Bolus Maintenance - Toddlers (BT)Rocuronium Bolus Maintenance -Children (BC)Rocuronium Bolus Maintenance - Adolescents (BA)Rocuronium Continuous Infusion Maintenance - Neonates (IN)Rocuronium Continuous Infusion Maintenance - Infants (II)Rocuronium Continuous Infusion Maintenance - Toddlers (IT)Rocuronium Continuous Infusion Maintenance - Children (IC)Rocuronium Continuous Infusion Maintenance - Adolescents (IA)
Started5818211976202520
Completed4618181756192218
Not completed1203220132

Outcome measures

PrimaryTotal Dose of Zemuron (Rocuronium) Administered

Total dose from administration of intubating dose to reappearance of T3 (the third twitch of a Train of Four \[TOF\] stimulation) after the last maintenance bolus dose or discontinuation of Zemuron (rocuronium) infusion (Per protocol \[PP\] data set)

Time frame:
during surgery
Reported as:
Mean · mg/kg
Total Dose of Zemuron (Rocuronium) Administered
mg/kgRocuronium Bolus Maintenance - Neonate (BN)Rocuronium Bolus Maintenance - Infants (BI)Rocuronium Bolus Maintenance - Toddlers (BT)Rocuronium Bolus Maintenance -Children (BC)Rocuronium Bolus Maintenance - Adolescents (BA)Rocuronium Continuous Infusion Maintenance - Neonates (IN)Rocuronium Continuous Infusion Maintenance - Infants (II)Rocuronium Continuous Infusion Maintenance - Toddlers (IT)Rocuronium Continuous Infusion Maintenance - Children (IC)Rocuronium Continuous Infusion Maintenance - Adolescents (IA)
Total Dose of Zemuron (Rocuronium) Administered0.91 ± 0.170.78 ± 0.070.86 ± 0.180.81 ± 0.100.96 ± 0.161.01 ± 0.370.84 ± 0.151.00 ± 0.251.26 ± 0.780.99 ± 0.37
SecondaryDuration of Recovery of T4/T1 Ratio (TOF Fourth Twitch to First Twitch) 70%

The time it takes for the the T4 to T1 ratio to reach 70%. The T4/T1 ratio is indicative of recovery. At complete recovery, the T4/T1 ratio is 1.0 (100%).

Time frame:
after surgery, from the reappearance of T3 after Zemuron(R) (rocuronium) infusion/last bolus dose of Zemuron(R) (rocuronium)
Reported as:
Mean · minutes
Duration of Recovery of T4/T1 Ratio (TOF Fourth Twitch to First Twitch) 70%
minutesRocuronium Bolus Maintenance - Neonate (BN)Rocuronium Bolus Maintenance - Infants (BI)Rocuronium Bolus Maintenance - Toddlers (BT)Rocuronium Bolus Maintenance -Children (BC)Rocuronium Bolus Maintenance - Adolescents (BA)Rocuronium Continuous Infusion Maintenance - Neonates (IN)Rocuronium Continuous Infusion Maintenance - Infants (II)Rocuronium Continuous Infusion Maintenance - Toddlers (IT)Rocuronium Continuous Infusion Maintenance - Children (IC)Rocuronium Continuous Infusion Maintenance - Adolescents (IA)
Duration of Recovery of T4/T1 Ratio (TOF Fourth Twitch to First Twitch) 70%29.62 ± 13.6033.25 ± 16.1722.65 ± 7.6216.19 ± 6.7028.04 ± 13.3343.32 ± 1.5333.25 ± 0.0023.08 ± 13.4018.37 ± 12.6927.59 ± 12.51
SecondaryDuration of Recovery of T4/T1 (TOF Fourth Twitch to First Twitch) Ratio 80%

The time it takes for the the T4 to T1 ratio to reach 80%. The T4/T1 ratio is indicative of recovery. At complete recovery, the T4/T1 ratio is 1.0 (100%).

Time frame:
after surgery, from the reappearance of T3 after Zemuron(R) (rocuronium) infusion/last bolus dose of Zemuron(R) (rocuronium)
Reported as:
Mean · minutes
Duration of Recovery of T4/T1 (TOF Fourth Twitch to First Twitch) Ratio 80%
minutesRocuronium Bolus Maintenance - Neonate (BN)Rocuronium Bolus Maintenance - Infants (BI)Rocuronium Bolus Maintenance - Toddlers (BT)Rocuronium Bolus Maintenance -Children (BC)Rocuronium Bolus Maintenance - Adolescents (BA)Rocuronium Continuous Infusion Maintenance - Neonates (IN)Rocuronium Continuous Infusion Maintenance - Infants (II)Rocuronium Continuous Infusion Maintenance - Toddlers (IT)Rocuronium Continuous Infusion Maintenance - Children (IC)Rocuronium Continuous Infusion Maintenance - Adolescents (IA)
Duration of Recovery of T4/T1 (TOF Fourth Twitch to First Twitch) Ratio 80%36.62 ± 17.1443.58 ± 21.4732.39 ± 12.8420.43 ± 9.7935.75 ± 19.4357.83 ± 12.3344.75 ± 0.0029.47 ± 16.6521.82 ± 14.5735.45 ± 17.02
SecondaryDuration of Recovery of T4/T1 (TOF Fourth Twitch to First Twitch) Ratio 90%

The time it takes for the the T4 to T1 ratio to reach 90%. The T4/T1 ratio is indicative of recovery. At complete recovery, the T4/T1 ratio is 1.0 (100%).

Time frame:
after surgery, from the reappearance of T3 after Zemuron(R) (rocuronium) infusion/last bolus dose of Zemuron(R) (rocuronium)
Reported as:
Mean · minutes
Duration of Recovery of T4/T1 (TOF Fourth Twitch to First Twitch) Ratio 90%
minutesRocuronium Bolus Maintenance - Neonate (BN)Rocuronium Bolus Maintenance - Infants (BI)Rocuronium Bolus Maintenance - Toddlers (BT)Rocuronium Bolus Maintenance -Children (BC)Rocuronium Bolus Maintenance - Adolescents (BA)Rocuronium Continuous Infusion Maintenance - Neonates (IN)Rocuronium Continuous Infusion Maintenance - Infants (II)Rocuronium Continuous Infusion Maintenance - Toddlers (IT)Rocuronium Continuous Infusion Maintenance - Children (IC)Rocuronium Continuous Infusion Maintenance - Adolescents (IA)
Duration of Recovery of T4/T1 (TOF Fourth Twitch to First Twitch) Ratio 90%28.25 ± 053.66 ± 14.5845.31 ± 18.2023.09 ± 10.9049.25 ± 31.7352.25 ± 050.75 ± 037.86 ± 18.4628.02 ± 21.4638.68 ± 16.08

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rocuronium Bolus Maintenance—1/64 (1.6%)10/64 (15.6%)
Rocuronium Continuous Infusion Maintenance—0/73 (0%)9/73 (12.3%)
Most frequent serious events
Most frequent serious events
EventRocuronium Bolus MaintenanceRocuronium Continuous Infusion Maintenance
postoperative wound infectionInfections and infestations1/640/73
Most frequent other events
Most frequent other events
EventRocuronium Bolus MaintenanceRocuronium Continuous Infusion Maintenance
procedural painInjury, poisoning and procedural complications10/649/73

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Rocuronium Bolus Maintenance - Neonate (BN)Rocuronium Bolus Maintenance - Infants (BI)Rocuronium Bolus Maintenance - Toddlers (BT)Rocuronium Bolus Maintenance -Children (BC)Rocuronium Bolus Maintenance - Adolescents (BA)Rocuronium Continuous Infusion Maintenance - Neonates (IN)Rocuronium Continuous Infusion Maintenance - Infants (II)Rocuronium Continuous Infusion Maintenance - Toddlers (IT)Rocuronium Continuous Infusion Maintenance - Children (IC)Rocuronium Continuous Infusion Maintenance - Adolescents (IA)Total
<=18 years5618181756192320137
Between 18 and 65 years00000000000
>=65 years00000000000
Sex: Female, Male
Sex: Female, Male(Participants)Rocuronium Bolus Maintenance - Neonate (BN)Rocuronium Bolus Maintenance - Infants (BI)Rocuronium Bolus Maintenance - Toddlers (BT)Rocuronium Bolus Maintenance -Children (BC)Rocuronium Bolus Maintenance - Adolescents (BA)Rocuronium Continuous Infusion Maintenance - Neonates (IN)Rocuronium Continuous Infusion Maintenance - Infants (II)Rocuronium Continuous Infusion Maintenance - Toddlers (IT)Rocuronium Continuous Infusion Maintenance - Children (IC)Rocuronium Continuous Infusion Maintenance - Adolescents (IA)Total
Female21186236111252
Male35171011331312885
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Bhattacharya ST, Jeffrey Koh J, Martin L, Suresh S, Frietsch T. Randomized, Multicenter Trial of Rocuronium in Neonates, Infants, Toddlers, Children & Adolescents [abstract]. Anesthesiology. 2009;111(5):A841.
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004, a primary completion of Aug 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2009, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2005
First posted
Jul 28, 2005
Start
Oct 2004
Primary completionActual
Aug 2007
CompletionActual
Sep 2007
Results first posted
Apr 15, 2009
Last update
Aug 24, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00124735
Responsible party
Sponsor
First posted
Jul 28, 2005
Start date
Oct 2004
Primary completion
Aug 2007
Completion
Sep 2007
Results posted
Apr 15, 2009
Last update
Aug 24, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rocuronium

Start the discussion